M6P/IGF2 receptor Inhibitors
1 drugsAbout M6P/IGF2 receptor
The M6P/IGF2 receptor mediates intracellular trafficking and signaling by binding M6P-tagged lysosomal enzymes and IGF2. It plays a crucial role in fundamental cellular processes.
Currently, there is no genetic evidence directly linking the M6P/IGF2 receptor to specific diseases, limiting confidence in target validation.
BRINEURA (BIOMARIN PHARM) is the only FDA-approved drug targeting M6P/IGF2 receptor, representing a biologic (other) modality for a single indication.
Top M6P/IGF2 receptor Drugs
BIOMARIN PHARM is the only company with an approved drug for this target.
The lack of competition represents an opportunity for new entrants, but also a risk due to limited market validation.
M6P/IGF2 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M6P/IGF2 receptor, using enzyme modality.
Exploring alternative modalities like small molecules could provide a competitive advantage.
M6P/IGF2 receptor Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on M6P/IGF2 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M6P/IGF2 receptor Drug Approval Timeline (2017 - 2017)
BRINEURA was first approved in 2017 and remains the only approved drug.
The absence of new approvals since 2017 suggests potential challenges or limited interest in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on M6P/IGF2 receptor. A trial counts if an approved drug acting on M6P/IGF2 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.